Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.35 |
| ▸ | CA1 | P00915 | 3/20 | 0.35 |
| ▸ | CA9 | Q16790 | 3/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | IDO1 | P14902 | 2/20 | 0.35 |
| ▸ | TDO2 | P48775 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6322141 | 1.00 | CA12 (0.35) | CA12CA1CA9CA2IDO1 | |
| SCHEMBL6325475 | 0.92 | CA12 (0.36) | CA12CA1CA9CA2IDO1 | |
| SCHEMBL6325477 | 0.92 | CA12 (0.36) | CA12CA1CA9CA2IDO1 | |
| SCHEMBL6318732 | 0.91 | IDO1 (0.35) | CA12CA1CA9CA2IDO1 | |
| SCHEMBL6318728 | 0.91 | IDO1 (0.35) | CA12CA1CA9CA2IDO1 | |
| SCHEMBL6321197 | 0.90 | IDO1 (0.35) | CA12CA1CA9CA2IDO1 | |
| SCHEMBL6321199 | 0.90 | IDO1 (0.35) | CA12CA1CA9CA2IDO1 | |
| SCHEMBL6320811 | 0.89 | IDO1 (0.36) | CA12CA1CA9CA2IDO1 | |
| SCHEMBL6321230 | 0.89 | IDO1 (0.36) | CA12CA1CA9CA2IDO1 | |
| SCHEMBL6321829 | 0.86 | IDO1 (0.38) | CA12CA1CA9CA2IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6855710-B2 | Substituted indolines with an inhibitory effect on various kinases and complexes of CDKs | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-02-15 | — | — | US | disclosed |
| US-20040058978-A1 | Novel substituted indolines with an inhibitory effect on various kinases and complexes of CDKs | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-03-25 | — | — | US | disclosed |
| EP-1115704-B1 | NOVEL SUBSTITUTED INDOLINONES WITH AN INHIBITORY EFFECT ON VARIOUS KINASES AND CYCLIN/CDK COMPLEXES | BOEHRINGER INGELHEIM PHARMA (DE) | 2003-06-18 | — | — | EP | disclosed |
| EP-1115704-A1 | NOVEL SUBSTITUTED INDOLINONES WITH AN INHIBITORY EFFECT ON VARIOUS KINASES AND CYCLIN/CDK COMPLEXES | Boehringer Ingelheim Pharma KG (DE) | 2001-07-18 | — | — | EP | disclosed |
| WO-2000018734-A1 | NOVEL SUBSTITUTED INDOLINONES WITH AN INHIBITORY EFFECT ON VARIOUS KINASES AND CYCLIN/CDK COMPLEXES | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2000-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058978-A1 | Novel substituted indolines with an inhibitory effect on various kinases and complexes of CDKs | CDK1, CDK2, CDK3 | CA12 4558/4885CA1 3035/4885CA9 3527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.